Sulfa drug allergy and treatment and doses
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive overview of sulfa drug allergy — its reactions, management, cross-reactivity, and key drug doses.
Sulfa Drug Allergy
What Are Sulfa Drugs?
Sulfonamides (sulfa drugs) include antibiotic sulfonamides (e.g., trimethoprim-sulfamethoxazole [TMP-SMX], sulfadiazine, sulfisoxazole, sulfacetamide) and non-antibiotic sulfonamide-containing drugs (e.g., furosemide, thiazides, sulfonylureas, celecoxib, dapsone). The key distinction matters for cross-reactivity.
Reactions & Clinical Presentation
| Reaction Type | Description |
|---|---|
| Maculopapular rash | Most common (T-cell mediated); appears 7–12 days after starting drug |
| Urticaria | Less common |
| Anaphylaxis | Rare; IgE-mediated |
| Stevens-Johnson Syndrome (SJS) / TEN | Rare but severe mucocutaneous reaction |
| DRESS (Hypersensitivity Syndrome) | Begins ~1–3 weeks after drug start; fever, rash, hepatitis, nephritis, pneumonitis, myocarditis/pericarditis, pancreatitis; may be fulminant |
| Crystalluria | Especially sulfadiazine in dehydrated/HIV patients |
| Hematologic | Hemolytic anemia (esp. G6PD deficiency), agranulocytosis, aplastic anemia, thrombocytopenia |
| Kernicterus | Neonates — bilirubin displacement from albumin; contraindicated near term pregnancy and neonates |
Skin and mucous membrane findings include morbilliform, scarlatiniform, urticarial, pemphigoid, purpuric, petechial rashes, erythema nodosum, erythema multiforme, Behçet syndrome, exfoliative dermatitis, and photosensitivity. Sulfonamide metabolites are primarily responsible for dermatologic reactions. — Goodman & Gilman's Pharmacological Basis of Therapeutics
HIV patients have a markedly increased risk: ~60% of HIV-positive patients develop TMP-SMX hypersensitivity vs. ~5% in HIV-negative patients. — Washington Manual of Medical Therapeutics
Cross-Reactivity
A critical clinical point: antibiotic sulfonamides and non-antibiotic sulfonamide-containing drugs carry LOW cross-reactivity.
- Only drugs with a free sulfonamide moiety (–SO₂NH₂) carry risk of cross-allergenicity.
- Most patients allergic to an antimicrobial sulfonamide can tolerate non-antimicrobial sulfonamide-containing drugs (furosemide, thiazides, sulfonylureas) — though avoidance may be preferred for severe reactions.
- Patients with sulfonamide antibiotic allergy are more likely to react to penicillin than to a non-antibiotic sulfonamide — suggesting common atopic risk rather than true cross-reactivity.
- Zonisamide (anticonvulsant) cross-reacts with sulfonamides.
- Darunavir contains a sulfonamide moiety — use with caution in sulfa-allergic patients. — Goodman & Gilman's; Andrews' Diseases of the Skin; Katzung's Pharmacology
Management
Mild reactions (maculopapular rash):
- Discontinue the drug if possible.
- Antihistamines for symptomatic relief.
- Desensitization if the drug is essential (especially TMP-SMX in HIV/PCP prophylaxis).
Severe reactions (SJS, TEN, DRESS, anaphylaxis):
- Immediately discontinue the drug — no rechallenge.
- Anaphylaxis: epinephrine, airway management, IV fluids, antihistamines, corticosteroids.
- DRESS: systemic corticosteroids; very slow taper (monitoring eosinophil count and organ function) — too rapid tapering causes relapse.
- SJS/TEN: supportive care, wound management; transfer to burn unit for severe TEN.
Desensitization (TMP-SMX):
- Indicated when the drug is essential (e.g., PCP treatment/prophylaxis, Nocardia, Toxoplasma in HIV).
- Oral desensitization preferred — lower risk of serious anaphylactic reaction vs. parenteral.
- Contraindicated if prior reaction was erythroderma or bullous (SJS/TEN).
- Must be performed in a monitored setting (ICU for high-risk patients).
- After desensitization, mild non-life-threatening reactions may still occur during therapy. — Harrison's Principles of Internal Medicine, 22e
Organ transplant patients with minor sulfa allergy: desensitization during transplant hospitalization. Major sulfa allergy: substitute with single daily dose of nitrofurantoin.
— Smith and Tanagho's General Urology
Key Drug Doses (TMP-SMX / Sulfonamides)
| Indication | Regimen |
|---|---|
| PCP treatment (HIV) | TMP 15–20 mg/kg/day + SMX 75–100 mg/kg/day in 3–4 divided doses; max TMP 20 mg/kg/day |
| PCP prophylaxis | TMP-SMX 1 DS tablet daily (or 3×/week); lower doses reduce adverse reactions |
| Toxoplasmosis | Pyrimethamine loading 2000 mg then 50–75 mg/day PO + Sulfadiazine 1–1.5 g PO every 6 h + Leucovorin 10–25 mg/day PO; minimum 6 weeks |
| Nocardia | TMP-SMX preferred; sulfisoxazole or sulfadiazine 6–8 g/day as alternative |
| UTI (sulfisoxazole) | 2–4 g loading dose, then 1–2 g PO four times daily for 5–10 days |
| Prevent crystalluria | Maintain urine output ≥1,200 mL/day (adults); alkalinize urine if needed |
Adjunctive corticosteroids should be added to PCP treatment when PaO₂ < 70 mmHg or alveolar-arterial gradient < 35 mmHg.
— Goodman & Gilman's Pharmacological Basis of Therapeutics
Drug Interactions
Sulfonamides potentiate the effects of:
- Warfarin (increased anticoagulation)
- Sulfonylureas (hypoglycemia)
- Hydantoin anticonvulsants (phenytoin toxicity)
Mechanism: inhibition of hepatic metabolism or displacement from albumin-binding. Monitor and adjust doses accordingly.
Contraindications
- Neonates / near-term pregnancy — risk of kernicterus
- G6PD deficiency — hemolytic anemia (especially topical silver sulfadiazine)
- Prior SJS/TEN from sulfonamide — absolute contraindication to rechallenge/desensitization
This is a shared conversation. Sign in to Orris to start your own chat.